Oxford Cannabinoid appoints Simbec-Orion to run first clinical trial on lead compound

Simbec-Orion is honoured to have been trusted by Oxford Cannabinoid Technologies to conduct this milestone first-in-human, Phase1 clinical trial of its lead compound, OCT461201 for Postherpetic Neuralgia (PHN) & Irritable Bowel Syndrome.

Chief Scientific Officer, Valentino Parravicini recently shared the excitement within OCT in reaching the clinical milestone and the significance of partnering with Simbec-Orion for the first-in-human Phase 1 clinical trial of their lead compound, OCT46120.

During the interview, he also shares the process his team undertook in the selection of their clinical partner, and what drove their final decision.

You can watch the whole interview here

Connect here to discuss your clinical trial needs with Simbec-Orion

Back to News Archive